Table 1.
Characteristics of the entire population
| Total | |
|---|---|
| N (%) | |
| All cases | 359 |
|
Mean age at diagnosis (range, years) |
54 (21–93) |
| CA125, mean (range), UI/mL | 69 (5–14,389) |
| Final FIGO stage | |
| IA | 141 (39.3) |
| IB | 20 (5.6) |
| IC1 | 35 (9.7) |
| IC2 | 40 (11.1) |
| IC3 | 12 (3.3) |
| IIA | 31 (8.6) |
| IIB | 50 (13.9) |
| IIIA1 | 30 (8.5) |
| Histology | |
| Serous | 143 (39.8) |
| Endometrioid | 101 (28.1) |
| Mucinous | 47 (13.1) |
| Clear cell | 57 (15.9) |
| Undifferentiated | 1 (0.3) |
| Mixed | 5 (1.4) |
| Others | 5 (1.4) |
| Residual tumor at the end of surgery | |
| No gross residual tumor | |
| Residual tumor | 359 (100.0) |
| 0 | |
| Gradinga | |
| 1 | 44 (15.9) |
| 2 | 98 (35.4) |
| 3 | 135 (48.7) |
| Type of BRCA mutationb | |
| No mutation | 87 (68.5) |
| BRCA1 mutation | 30 (23.6) |
| BRCA2 mutation | 9 (7.1) |
| BRCA1-2 mutation | 1 (0.8) |
| Inflammatory markers* | |
| SII | |
| < 1000 | 263 (73.3) |
| ≥ 1000 | 96 (26.7) |
| NLR | |
| < 3 | 236 (65.7) |
| ≥ 3 | 123 (34.3) |
| PLR | |
| < 200 | 269 (74.9) |
| ≥ 200 | 90 (25.1) |
| ELR | |
| < 0.03 | 60 (16.7) |
| ≥ 0.03 | 299 (83.3) |
| ENL | |
| < 0.6 | 291 (81.1) |
| ≥ 0.6 | 68 (18.9) |
| FAR | |
| < 10 | 226 (63.0) |
| ≥ 10 | 133 (37.0) |
| MLR | |
| < 0.2 | 156 (43.4) |
| ≥ 0.2 | 203 (56.5) |
FIGO International Federation of Gynecology and Obstetrics; BRCA Breast Cancer gene; NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, ELR eosinophil-lymphocyte ratio, MLR monocyte-lymphocyte ratio, systemic immune inflammation index (SII = platelet x neutrophil/lymphocyte), ENL (eosinophil x neutrophil)/lymphocyte, FAR fibrinogen-albumin ratio
*Calculated with ROC curves
aData calculated on 277 patients due to lack of data of 82 patients
bData calculated on 127 patients due to lack of data of 232 patients